XML 76 R67.htm IDEA: XBRL DOCUMENT v3.21.1

Disaggregation of Revenues and Concentration Risk - Schedule of Percentage of Total Consolidated Accounts Receivables (Details)	3 Months Ended			12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020		Dec. 31, 2020
Concentration risk, percentage	100.00%	100.00%
Pharma Services Company A [Member]
Concentration risk, percentage	20.00%	0.00%	[1]
Pharma Services Company A [Member] | Accounts Receivable [Member]
Concentration risk, percentage	24.00%			35.00%
Medicare for DetermaRx [Member]
Concentration risk, percentage	27.00%	0.00%
Medicare for DetermaRx [Member] | Accounts Receivable [Member]
Concentration risk, percentage	16.00%			45.00%
Pharma Services Company B [Member]
Concentration risk, percentage	15.00%	0.00%	[1]
Pharma Services Company B [Member] | Accounts Receivable [Member]
Concentration risk, percentage	18.00%			0.00%
Medicare Advantage for DetermaRx [Member]
Concentration risk, percentage	27.00%	0.00%
Medicare Advantage for DetermaRx [Member] | Accounts Receivable [Member]
Concentration risk, percentage	38.00%			0.00%
[1] Less than 10%

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=OCX_PharmaservicesCompanyAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=OCX_MedicareforDetermaRxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=OCX_PharmaServicesCompanyBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=OCX_MedicareAdvantageforDetermaRxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: